References

tbjournal

Туберкулез и социально значимые заболевания

Tuberculosis and socially significant diseases

2413-03462413-0354

ООО «Ин-Тренд

tbjournal-378

Research Article

ОБЗОР ЛИТЕРАТУРЫ

LITERATURE REVIEW

Лекарственная чувствительность клинических изолятов M. avium complex

DRUG SUSCEPTIBITITY OF M. AVIUM COMPLEX CLINICAL STRAINS

Литвинов

В. И.

Litvinov

V. I.

Литвинов Виталий Ильич – научный руководитель ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы», доктор медицинских наук, профессор, академик РАН

107014, г. Москва, ул. Стромынка, д. 10Тел.: + 7 (495) 268-04-15

mnpcbtlv@yandex.ru

Макарова

М. В.

Makarova

M. V.

Макарова Марина Витальевна – ведущий научный сотрудник отдела проблем лабораторной диагностики туберкулеза и патоморфологии ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы», доктор биологических наук

107014, г. Москва, ул. Стромынка, д. 10Тел.: + 7 (916) 688-98-25

makarova75@yandex.ru

Хачатурьянц

Е. Н.

Khachaturiants

E. N.

Хачатурьянц Елена Николаевна – врач-бактериолог ЦБЛ ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»

107014, г. Москва, ул. Стромынка, д. 10Тел. + 7 (915) 302-15-43

hen65b@mail.ru

Краснова

М. А.

Krasnova

M. A.

Краснова Мария Александровна – ведущий научный сотрудник отдела проблем лабораторной диагностики туберкулеза и патоморфологии ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы», кандидат медицинских наук

107014, г. Москва, ул. Стромынка, д. 10Тел.: + 7 (495) 603-30-33

rna68@rambler.ru

Гунтупова

Л. Д.

Guntupova

L. D.

Гунтупова Лидия Доржиевна – заведующая отделением легочного туберкулеза клинико-диагностического центра ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы», кандидат медицинских наук

107014, г. Москва, ул. Стромынка, д. 10Тел.: + 7 (499) 267-57-92

guntupov@mail.ru

ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»Russian Federation

2017

30012025

011926

2025

Литвинов В.И., Макарова М.В., Хачатурьянц Е.Н., Краснова М.А., Гунтупова Л.Д.

Litvinov V.I., Makarova M.V., Khachaturiants E.N., Krasnova M.A., Guntupova L.D.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.tb-journal.ru/jour/article/view/378

В обзоре литературы охарактеризованы результаты применения основных методов, применяемых для изучения лекарственной чувствительности микобактерий комплекса M. avium-intracellulare (МАС). При этом основное внимание обращено на препараты, используемые при исследованиях с помощью количественного микрометода серийных разведений (Sensititre SLOMYCO).

In this review characterized the results of using of the main DST methods designed for investigation of drug susceptibility of mycobacteria of M. avium-intracellulare complex (МАС). The focus was on the drugs used in studies by serial microdilution method (Sensititre SLOMYCO).

лекарственная чувствительностьМАСSensititre

drug susceptibilityМАСSensititre

References1

Андреевская С.Н., Ларионова Е.Е., Смирнова Т.Г. и др. Лекарственная чувствительность медленнорастущих нетуберкулезных микобактерий // Туберкулез и болезни легких. – 2016. – № 4. – С. 43-50.

Лабораторные исследования при туберкулезе / под ред. В.И. Литвинова, А.М. Мороза. – М.: МНПЦБТ, 2013. – 343 с.

Литвинов В.И., Макарова М.В., Краснова М.А. Нетуберкулезные микобактерии. – М.: МНПЦБТ, 2008. – 255 с.

Нетуберкулезные микобактерии, микобактериозы / под ред. В.И. Литвинова, Е.М. Богородской, С.Е. Борисова. – М.: МНПЦБТ, 2014. – 254 с.

Оттен Т.Ф., Васильев А.В. Микобактериоз. – СПб.: Мед. пресса, 2005. – 224 с.

Abuali M.M., Katariwala R., LaBombardi V.J. A comparison of the Sensititre®MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis // Eur. J. Clin. Microbiol. Infect. Dis. – 2011. – Vol. 31. – N. 5. – P. 835-839.

Ahmed I., Jabeen K., Hasan R. Identification of non-tuberculous mycobacteria isolated from clinical specimens at a tertiary care hospital: a cross-sectional study // BMC Infect. Dis. – 2013. – Vol. 13. – Р. 493.

Alcaide F., Calatayud L., Santín M., Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii // Antimicrob. Agents. Chemother. – 2004. – Vol. 48. – N. 12. – Р. 4562-4565.

Alcaide F., Esteban J., González-Martin J., Palacios J. Methods for determining the antimicrobial susceptibility of mycobacteria // Enferm. Infec. Microbiol. Clin. – 2016. – S0213-005X(16). – Р. 30103-3.

Babady N., Hall L., Abbenyi A. et al. Evaluation of Mycobacterium aviumcomplex clarithromycin susceptibility testing using SLOMYCO Sensititre panels and Just-One strips // J. Clin. Microbiol. – 2010. – Vol. 48. – N. 5. – Р. 1749-1752.

Benson C., Williams P., Cohn D. et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team // J. Infect. Dis. – 2000. – Vol.181. – N. 4. – Р. 1289-1297.

Brown-Elliott B., Griffith D., Wallace R. Diagnosis of nontuberculous mycobacterial infections // J. Clin. Lab. Med. – 2002. – Vol. 22. – Р. 911-925.

Brown-Elliott B., Wallace R. Infections caused by nontuberculous mycobacteria // In: Principles and Practice of Infectious Disease / ed. by G. Mandell. – 2005. – Vol. 2. – Р. 2909-2916.

Brown-Elliott B., Nash K., Wallace R. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria // Clin. Microbiol. Rev. – 2012. – Vol. 25. – N. 3. – Р. 545-582.

Brown-Elliott B., Iakhiaeva E., Griffith D. et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates // J. Clin. Microbiol. – 2013. – Vol. 51. – N. 10. – Р. 3389-3394.

Cavusoglu C., Soyler I., Akinci P. Activities of Linezolid against nontuberculous mycobacteria // New. Microbiol. – 2007. – Vol. 30. – N. 4. – Р. 411-414.

CLSI. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard – second edition // CLSI document M24-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2011. [Электронный документ] URL: http://shop.clsi.org/site/Sample_pdf/M24A2_sample.pdf (Дата обращения 12.10.2016).

Chaisson R., Benson C., Dube M. et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team // Ann. Intern. Med. – 1994. – Vol. 121. – N. 12. – Р. 905-911.

Craft J., Notario G., Grosset J., Heifets L. Clarithromycin resistance and susceptibility patterns of Mycobacterium aviumstrains isolated during prophylaxis for disseminated infection in patients with AIDS // Clin. Infect. Dis. – 1998. – Vol. 27. – N. 4. – Р. 807-812.

Daley C. Mycobacterial infections // Semin. Respir. Crit. Care Med. – 2013. – Vol. 34. – N. 1. – Р. 1-22.

Deshpande D., Srivastava S., Meek C. et al. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacteriumavium infection // Antimicrob. Agents. Chemother. – 2010. – Vol. 54. – N. 6. – Р. 2534-2539.

Deshpande D., Gumbo T. Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium // Future Microbiol. – 2011. – Vol. 6. – N. 4. – Р. 433-439.

Duan H., Liang Q., Chu N., Huang H. Macrolide and linezolid susceptibility testing for Mycobacterium intracellulare isolates // Zhonghua J. He He Hu Xi ZaZhi. – 2014. – Vol. 37. – N. 4. – Р. 266-269.

Dubé M., Sattler F., Torriani F. et al. The randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy California Collaborative Treatment Group // J. Infect. Dis. – 1997. – Vol. 176. – N. 5. – Р. 1225-1232.

Falkinham J. Current epidemiologic trends of the nontuberculous mycobacteria (NTM) // Curr. Environ. Health. Rep. – 2016. – Vol. 3. – N. 2. – P. 161-167.

Glassroth J. Pulmonary disease due to nontuberculous mycobacteria // Chest. – 2008. – Vol. 133. – N. 1. – Р. 243-251.

Griffith D., Aksamit T., Brown-Elliott B. et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases // J. Respir. Crit. Care Med. – 2007. – Vol. 175. – N. 4. – Р. 367-416.

Hall L., Jude K. P., Clark S.L. et al. Evaluation of the SensititreMycoTB plate for susceptibility testing of the Mycobacterium tuberculosis сomplex against first- and second-line agents //J. Clin. Microbiol. – 2012. –Vol. 50. – N. 11. – Р. 3732-3734.

Heifets L. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs // Antimicrob. Agents. Chemother. – 1988(а). – Vol. 32. – N. 8. – Р. 1131-1136.

Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology // Am. Rev. Respir. Dis. – 1988(b). – Vol. 137. – N. 5. – P. 1217-1222.

Heifets L. Antimycobacterial drugs // Semin. Respir. Infect. – 1994. – Vol. 9. – N. 2. –Р. 84-103.

Heifets L. Clarithromycin against Mycobacterium avium complex infections // Tuber. Lung. Dis. – 1996(а). – Vol. 77. – N. 1. – Р. 19-26.

Heifets L. Clinical mycobacteriology. Drug susceptibility testing // Clin. Lab. Med. – 1996(b). – Vol. 16. – N. 3. – Р. 641-656.

Heifets L. Susceptibility testing of Mycobacterium avium complex isolates // Antimicrob. Agents. Chemother. – 1996(c). –Vol. 40. – N. 8. – P. 1759-1767.

Heifets L. Mycobacterial infections caused by nontuberculous mycobacteria // Semin. In Respir. Crit. Care Med. – 2004. – Vol.25. – N. 3. – Р. 283-295.

Heifets L., Iseman M., Lindholm-Levy P. Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis // Antimicrob. Agents. Chemother. – 1986. – Vol. 30. – N. 6. –Р. 927-932.

Heifets L., Iseman M., Lindholm-Levy P. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects // Am. Rev. Respir. Dis. – 1988. – Vol. 137. – N. 3. – Р. 711-715.

Heifets L., Lindholm-Levy P. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis // Antimicrob. Agents. Chemother. – 1989. – Vol. 33. – N. 8. – Р. 1298-1301.

Heifets L., Iseman M. Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility // N. Engl. J. Med. – 1990. – Vol. 323. – N. 6. – Р. 419-420.

Heifets L., Lindholm-Levy P., Flory M. Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosis // Am. Rev. Respir. Dis. – 1991. – Vol. 143. – N. 2. – Р. 268-270.

Heifets L., Lindholm-Levy P., Comstock R. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium // Am. Rev. Respir. Dis. – 1992(а). – Vol. 145. – N. 4. – Pt. 1. – Р. 856-858.

Heifets L., Lindholm-Levy P., Comstock R. Bacteriostatic and bactericidal activities of gentamycin alone and in combination with clarithromycin against Mycobacterium avium // Antimicrob. Agents. Chemother. – 1992(b). – Vol. 36. – N. 8. – Р. 1695-1698.

Heifets L., Jenkins P. Speciation of micobacteria in clinical laboratories // In: Mycobacteria. Basic aspects / ed. by P. Gangadharam, P. Jenkins. – NY.: Chapman a Hall (Inf. Thompson Publishing), 1998. – Vol. 1. – Р. 308-350.

Horsburgh C., Mason U., Heifets L. et al. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing // Am. Rev. Respir. Dis. – 1987. – Vol. 135. – N. 2. – Р. 418-421.

Iseman M. Medical management of pulmonary disease caused by M. Avium complex // Clin. Chest. Med. – 2003. – Vol. 23. – Р. 633-641.

Kawahara S., Tada A., Nagare H. Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria // Kekkaku. – 2001. – Vol. 76. – N. 4. – Р. 357-362.

Klemens S., Grossi M., Cynamon M. Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex // Antimicrob. Agents.

Chemother. – 1994. – Vol. 38. – N. 2. – Р. 234-237.

Klopman G., Wang S., Jacobs M. et al. Anti-Mycobacterium avium activity of quinolones: in vitro activities // Antimicrob. Agents. Chemother. – 1993(а). – Vol. 37. – N. 9. – Р. 1799-1806.

Klopman G., Wang S., Jacobs M., Ellner J. Anti-Mycobacterium avium activity of quinolones: structure-activity relationship studies // Antimicrob.Agents. Chemother. – 1993(b). – Vol. 37. – N. 9. – Р. 1807-1815.

Klopman G., Li J., Wang S. et al. In vitroanti-Mycobacterium avium activities of quinolones: predicted active structures and mechanistic considerations // Antimicrob. Agents. Chemother. – 1994. – Vol. 38. – N. 8. – Р. 1794-1802.

Lee J., Armstrong D., Ssengooba W. et al. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second – line drugs // Antimicrob. Agents Chemother. – 2014. – Vol. 58. – N. 1. – Р. 11-18.

Li G., Lian L., Wan L. et al. Antimicrobial susceptibility of standard strains of nontuberculous mycobacteria by microplate Alamar Blue assay // PLoS. One. – 2013. – Vol. 8. – N. 12. – e84065.

Molicotti P., Ortu S., Bua A. et al. In vitro efficacy of Linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria // New Microbiol. – 2006. – Vol. 29. – N. 4. – Р. 275-280.

Moon S., Park H., Kim S. et al., Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease // Antimicrob. Agents. Chemother. – 2016. – pii: AAC. 01240-16.

Mor N., Vanderkolk J., Mezo N., Heifets L. Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium // Antimicrob. Agents. Chemother. – 1994. – Vol. 38. – N. 12. – Р. 2738-2742.

Nie W., Duan H., Huang H. et al. Species identification and clarithromycin susceptibility testing of 278 clinical nontuberculosis mycobacteria isolates // Biomed. Res. Int. – 2015. – Р. 506-598.

Park J. Recent advances in tuberculosis and nontuberculous mycobacteria lung disease // Tuberc. Respir. Dis. (Seoul). – 2013. – Vol. 74. – N. 6. – Р. 251-255.

Rastogi N., Bauriaud R., Bourgoin A. et al. French multicenter study involving eight test sites for radiometric determination of activities of 10 antimicrobial agents against Mycobacterium avium complex // Antimicrob. Agents. Chemother. – 1995. – Vol. 39. – N. 3. – Р. 638-644.

Raszka W., Skillman L., McEvoy P. In vitro susceptibility of clinical isolates of Mycobacterium avium and M. intracellulare to folate antagonists //

Diagn. Microbiol. Infect. Dis. – 1994. – Vol. 18. – N. 3. – Р. 201-204.

Renvoisé A., Bernard C., Veziris N. et al. Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacteriumintracellulare // J. Clin. Microbiol. – 2014. – Vol. 52. – N. 12. –Р. 4439-4440.

Ryu Y., Koh W., Daley C. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians’ perspectives // Tuberc. Respir. Dis. (Seoul). – 2016. – Vol. 79. – N. 2. – P. 74-84.

Shafran S. Clarithromycin prophylaxis for disseminated Mycobacterium avium complex infection – efficacy and acquired resistance // Clin. Infect. Dis. – 1998(a). – Vol. 27. – N. 4. – Р. 813-815.

Shafran S. Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals // Int. J. Infect. Dis. – 1998(b). – Vol. 3. – N. 1. – Р. 39-47.

Siddiqi S., Heifets L., Cynamon M. et al. Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates // J. Clin. Microbiol. – 1993. – Vol. 31. – N. 9. – Р. 2332-2338.

Slany M., Ulmann V., Slana I. Avian mycobacteriosis: still existing threat to humans // Eur. J. Clin. Microbiol. Infect. Dis. – 2014. – Vol. 33. – N. 3. – P. 347-358.

Stout J., Koh W., Yew W. Update on pulmonary disease due to non-tuberculous mycobacteria // Int. J. Infect. Dis. – 2016. –Vol. 45. – P. 123-134.

Tomioka H., Sato K., Saito H. In vitro susceptibilities of Mycobacteriumavium and Mycobacterium intracellulare to various drugs // Kekkaku. – 1991. – Vol. 66. – N. 7. – Р. 489-492.

Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections // Clin. Microbiol. Infect. – 2009. – Vol. 15. – N. 10. – Р. 906-910.

Tsukamura M., Ichiyama S. Correlation of minimal inhibitory concentration values of antituberculosis agents against Mycobacterium avium complex strains with incubation period // Kekkaku. – 1988(а). – Vol. 63. – N. 2. – Р. 107-110.

Tsukamura M. Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by Mycobacterium aviumcomplex // Am. Rev. Respir. Dis. – 1988(b). – Vol. 137. – N. 1. – Р. 144-148.

van Ingen J., Egelund E., Levin A. et al.The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment // Am. J. Respir. Crit. Care Med. – 2012(а). – Vol. 186. – N. 6. – Р. 559-565.

van Ingen J., Totten S., Helstrom N. et al. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease // Antimicrob. Agents. Chemother. – 2012(b). – Vol. 56. – N. 12. – Р. 6324-6327.

van Ingen J. Diagnosis of nontuberculous mycobacterial infections // Semin. Respir. Crit. Care Med. – 2013. – Vol. 34. – N. 1. – Р. 103-109.

Venugopal D., Kumar S., Isa M., Bose M. Drug resistance profile of human Mycobacterium avium complex strains from India // Indian. J. Med. Microbiol. – 2007. – Vol. 25. – N. 2. – Р. 115-120.

Wallace R., Brown-Elliott B., Crist C. et al. Comparison of the in vitro activity of the glycylcyclinetigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria // Antimicrob. Agents. Chemother. – 2002. – Vol. 46. – N. 10. – Р. 3164-3167.

Ward T., Rimland D., Kauffman C. et al. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium // Clin. Infect. Dis. – 1998. – Vol. 27. – N. 5. – Р. 1278-1285.

Woods G. Susceptibility testing for mycobacteria // Clin. Infect. Dis. – 2000. – Vol. 31. – N. 5. – Р. 1209-1215.

Woods G., Williams-Bouyer N., Wallace R. et al. Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex // J. Clin. Microbiol. – 2003. – Vol. 41. – N. 2. – Р. 627-631.

Xu H., Jiang R., Li L. Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis // Eur. J. Clin. Microbiol. Infect. Dis. – 2014. – Vol. 33. – N. 3. – P. 347-358.

Zhang Z, Pang Y, Wang Y et al. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China // Int. J. Antimicrob. Agents. – 2015. – Vol. 45. – N. 5. – P. 491-495.

The authors declare that there are no conflicts of interest present.